Empowering mental health professionals with peer-reviewed psychiatric research and insights

Page 59

More JCP Articles

JCP
SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression
JCP
JCP
JCP
JCP
JCP
JCP
JCP
JCP
JCP
JCP
Identifying Patients With Bipolar I Disorder Who Would Benefit From Maintenance Therapy With a Long-Acting Injectable Antipsychotic
JCP